These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 8424807

  • 1. Effect of sodium benzoate on cerebral and hepatic energy metabolites in spf mice with congenital hyperammonemia.
    Ratnakumari L, Qureshi IA, Butterworth RF.
    Biochem Pharmacol; 1993 Jan 07; 45(1):137-46. PubMed ID: 8424807
    [Abstract] [Full Text] [Related]

  • 2. Effect of L-carnitine on cerebral and hepatic energy metabolites in congenitally hyperammonemic sparse-fur mice and its role during benzoate therapy.
    Ratnakumari L, Qureshi IA, Butterworth RF.
    Metabolism; 1993 Aug 07; 42(8):1039-46. PubMed ID: 8102193
    [Abstract] [Full Text] [Related]

  • 3. Effects of congenital hyperammonemia on the cerebral and hepatic levels of the intermediates of energy metabolism in spf mice.
    Ratnakumari L, Qureshi IA, Butterworth RF.
    Biochem Biophys Res Commun; 1992 Apr 30; 184(2):746-51. PubMed ID: 1575747
    [Abstract] [Full Text] [Related]

  • 4. Free and esterified coenzyme A in the liver and muscles of chronically hyperammonemic mice treated with sodium benzoate.
    Michalak A, Qureshi IA.
    Biochem Mol Med; 1995 Apr 30; 54(2):96-104. PubMed ID: 8581365
    [Abstract] [Full Text] [Related]

  • 5. Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the ornithine transcarbamylase-deficient sparse-fur mouse.
    Batshaw ML, Hyman SL, Coyle JT, Robinson MB, Qureshi IA, Mellits ED, Quaskey S.
    Pediatr Res; 1988 Apr 30; 23(4):368-74. PubMed ID: 3374991
    [Abstract] [Full Text] [Related]

  • 6. Tissue acylcarnitine and acyl-coenzyme A profiles in chronically hyperammonemic mice treated with sodium benzoate and supplementary L-carnitine.
    Michalak A, Qureshi IA.
    Biomed Pharmacother; 1995 Apr 30; 49(7-8):350-7. PubMed ID: 8562862
    [Abstract] [Full Text] [Related]

  • 7. Restoration of hepatic cytochrome c oxidase activity and expression with acetyl-L-carnitine treatment in spf mice with an ornithine transcarbamylase deficiency.
    Mawal YR, Rama Rao KV, Qureshi IA.
    Biochem Pharmacol; 1998 Jun 01; 55(11):1853-60. PubMed ID: 9714304
    [Abstract] [Full Text] [Related]

  • 8. [Profile of hepatic and muscular acylcarnitines in chronically hyperammonemic mice after an acute treatment with sodium benzoate: dose-response study].
    Michalak A, Qureshi IA.
    Ann Biol Clin (Paris); 1993 Jun 01; 51(10-11):879-85. PubMed ID: 8210064
    [Abstract] [Full Text] [Related]

  • 9. Development and inducibility of the hepatic and renal hippurate-synthesizing system in sparse-fur (spf) mutant mice with ornithine transcarbamylase deficiency.
    Qureshi IA, Lebel S, Letarte J.
    Biochem Int; 1989 Sep 01; 19(3):657-66. PubMed ID: 2818615
    [Abstract] [Full Text] [Related]

  • 10. Sodium benzoate inhibits fatty acid oxidation in rat liver: effect on ammonia levels.
    Kalbag SS, Palekar AG.
    Biochem Med Metab Biol; 1988 Oct 01; 40(2):133-42. PubMed ID: 3190922
    [Abstract] [Full Text] [Related]

  • 11. Developmental study of hepatic glutamine synthetase in a mouse model of congenital hyperammonemia.
    Skarpetas A, Mawal Y, Qureshi IA.
    Biochem Mol Biol Int; 1997 Sep 01; 43(1):133-9. PubMed ID: 9315291
    [Abstract] [Full Text] [Related]

  • 12. Amino acids in the rat liver and plasma and some metabolites in the liver after sodium benzoate treatment.
    Palekar AG, Kalbag SS.
    Biochem Med Metab Biol; 1991 Aug 01; 46(1):52-8. PubMed ID: 1931156
    [Abstract] [Full Text] [Related]

  • 13. Activity of the glycine cleavage system in hyperammonemia treated with benzoate.
    Kodama H, Fujiwara K, Motokawa Y, Tajiri H, Nose O, Kamoshita S.
    Tohoku J Exp Med; 1983 Jul 01; 140(3):337-8. PubMed ID: 6623463
    [Abstract] [Full Text] [Related]

  • 14. The importance of glyoxylate and other glycine precursors in the hepatic and renal conjugation of benzoate in normal and hyperammonemic mice.
    Qureshi IA, Clermont P, Letarte J.
    Can J Physiol Pharmacol; 1989 Nov 01; 67(11):1426-30. PubMed ID: 2627683
    [Abstract] [Full Text] [Related]

  • 15. Reduction in the MK-801 binding sites of the NMDA sub-type of glutamate receptor in a mouse model of congenital hyperammonemia: prevention by acetyl-L-carnitine.
    Rao KV, Qureshi IA.
    Neuropharmacology; 1999 Mar 01; 38(3):383-94. PubMed ID: 10219976
    [Abstract] [Full Text] [Related]

  • 16. [Carnitine levels in muscle in mice with hyperammonemia: effect of treatment with sodium benzoate].
    Michalak A, Qureshi IA.
    Can J Physiol Pharmacol; 1993 Jul 01; 71(7):439-46. PubMed ID: 8242478
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Transient hyperammonemia during aging in ornithine transcarbamylase-deficient, sparse-fur mice.
    Gushiken T, Yoshimura N, Saheki T.
    Biochem Int; 1985 Nov 01; 11(5):637-43. PubMed ID: 4091843
    [Abstract] [Full Text] [Related]

  • 20. Developmental deficiency of the cholinergic system in congenitally hyperammonemic spf mice: effect of acetyl-L-carnitine.
    Ratnakumari L, Qureshi IA, Maysinger D, Butterworth RF.
    J Pharmacol Exp Ther; 1995 Jul 01; 274(1):437-43. PubMed ID: 7616428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.